InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
tykundegex Free
10/18/17 9:33 AM
profile icon
tykundegex Free
06/08/16 3:35 PM
profile icon
tykundegex Free
01/04/16 8:37 PM
profile icon
tykundegex Free
01/06/15 10:13 AM
profile icon
tykundegex Free
07/09/14 10:15 AM
profile icon
tykundegex Free
07/03/14 2:56 PM
profile icon
tykundegex Free
07/02/14 8:34 AM
profile icon
tykundegex Free
02/07/14 2:14 PM
profile icon
68-Tele Free
05/08/13 1:27 PM
profile icon
tykundegex Free
02/07/13 5:19 AM
profile icon
tykundegex Free
11/05/12 11:29 AM
profile icon
tykundegex Free
10/29/12 9:40 AM
profile icon
tykundegex Free
10/11/12 4:25 AM
profile icon
tykundegex Free
10/03/12 7:41 AM
profile icon
tykundegex Free
08/02/12 6:36 AM
profile icon
tykundegex Free
06/05/12 6:18 AM
profile icon
tykundegex Free
03/22/12 8:35 AM
profile icon
tykundegex Free
03/22/12 5:08 AM
profile icon
tykundegex Free
03/21/12 1:44 PM
profile icon
tykundegex Free
03/21/12 5:04 AM
profile icon
tykundegex Free
03/15/12 6:03 AM
profile icon
tykundegex Free
03/07/12 1:12 PM
profile icon
tykundegex Free
01/10/12 6:18 AM
profile icon
tykundegex Free
10/21/11 11:47 AM
profile icon
tykundegex Free
10/04/11 11:14 AM
profile icon
tykundegex Free
10/04/11 3:55 AM
profile icon
tykundegex Free
09/05/11 4:33 AM
profile icon
tykundegex Free
09/05/11 4:32 AM
profile icon
tykundegex Free
08/22/11 3:20 AM
profile icon
tykundegex Free
08/19/11 6:08 AM
profile icon
tykundegex Free
08/17/11 6:20 AM
profile icon
tykundegex Free
08/15/11 4:46 AM
profile icon
tykundegex Free
07/14/11 6:49 AM
profile icon
tykundegex Free
07/14/11 6:45 AM
profile icon
tykundegex Free
07/14/11 6:25 AM
profile icon
tykundegex Free
07/14/11 6:21 AM

Addex Therapeutics Ltd. (fka ADDXF) RSS Feed

Followers
2
Posters
3
Posts (Today)
0
Posts (Total)
43
Created
07/14/11
Type
Free
Moderators
Addex Pharmaceuticals (ADDXF on the US Pinks and ADXN in Switzerland) discovers and develops allosteric modulators for human health. The company uses its proprietary discovery platform to target cell surface receptors that are recognized as having therapeutic potential for treating diseases of the central nervous system, metabolic disorders or inflammation.

Best overview of the company's business is this presentation by the new CEO from September 27, 2011: 
http://www.addexpharma.com/fileadmin/user_upload/Conference_slideshows/110925_Addex_Jefferies_FINAL.pdf

Liquidity on US Pinks is near zero -- this company trades best on SWX (Swiss) as "ADXN" or in Germany as "APE" (also pretty bad volume)

http://www.addexpharma.ch/

Addex Pharmaceuticals discovers and develops an emerging class of small molecule drugs, called allosteric modulators, which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. The company uses its proprietary discovery platform to address receptors and other proteins that are recognized as attractive targets for modulation of important diseases with unmet medical needs. The Company's two lead products are being investigated in Phase IIa clinical testing: dipraglurant  (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and, ADX71149(mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals, Inc., to treat schizophrenia. Another partner, Merck & Co., Inc., is developing mGluR4 PAM for Parkinson's disease. Addex also is advancing several preclinical programs including: mGluR2 NAM for treating Alzheimer's disease and depression; GLP-1R PAM for type 2 diabetes; FSHR NAM for endometriosis and benign prostatic hyperplasia; and GABA-BR PAM for chronic pain, urinary incontinence and other disorders. In addition, Addex has discovery programs to identify allosteric modulators of: receptor tyrosine kinase (RTK) superfamily, including TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer's, Parkinson's and Huntington's diseases); TNF receptor superfamily, including TNFR1 NAM for inflammation (e.g. rheumatoid arthritis); and, interleukin receptor family, such as IL1R1 NAM for gout and type II diabetes.

About Addex

Originally conceived as a specialty pharma company focused on addiction, Addex was founded by pharmaceutical industry researchers with €10 million from top European venture capital investors in 2002.  While trying to discover a  new drug to treat addiction, the Addex researchers developed a scalable process for discovering drug-like allosteric modulators. They quickly recognized that this innovation could become a discovery platform that was much more broadly applicable than the company's original business plan had envisioned. Therefore, in 2003, the management adapted and re-focused Addex on industrializing the allosteric modulator discovery and development process.

Although a handful of allosteric modulators have been discovered and are now marketed drugs, they were identified by serendipity. Addex is the first company to focus on industrializing the process of finding and developing allosteric modulators. In order to leverage and build upon its first mover advantage, the company has assembled a team of drug developers with significant pharmaceutical industry experience, including chemists, molecular biologists, biochemists, veterinarians, physicians and others. Advised by some of the world's leading researchers, the team has focused not only on building knowledge of allosteric modulation but also generated a tailored allostery-biased library of over 70,000 compounds as well as proprietary high-throughput biological assays that allow detection, optimization and confirmation of the mechanism of action for allosteric compounds.

Building on these internally discovered tools, Addex has grown into a fully integrated pharmaceutical discovery and development company with significant clinical development capabilities and a diverse pipeline of proprietary compounds that address a broad range of major diseases. Because the allosteric approach is well differentiated, many of the therapeutic targets Addex is pursuing are clinically validated, thereby reducing the risk profile of its products. Addex has a growing portfolio of patents and patent applications covering the composition of matter and methods of use for its allosteric modulators.

Addex has raised a total of CHF 263 Million to date. For more details see our funding history.
Board Info
Posts Today
0
Posts (Total)
43
Posters
3
Moderators
New Post